omblastug
Phase 2
Novartisomblastug is one of 10 therapeutic programs targeting Warm Autoimmune Hemolytic Anemia. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
12 competitors in Warm Autoimmune Hemolytic Anemia
#DrugCompanyPhaseTrials
1Wayrilz
GGenzyme, a Sanofi Company
Phase 3
Ianalumab
NovartisPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Obexelimab
ZZenas BioPharma (USA), LLC
Phase 3
ALXN1830
AstraZenecaPhase 2
M281
MMomenta Pharmaceuticals, Inc.
Phase 3
Fabhalta
Johnson & JohnsonPreclinical
ANX005
AAnnexon, Inc.
Phase 2
RVT-1401
IImmunovant Sciences GmbH
Phase 2
omblastug
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for omblastug. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company